Key Highlights

  • CareDx received $171.7 million in cash from the sale of its Swedish unit to Eurobio.
  • The Naveris acquisition cost $161.8 million in cash, with further contingency payments possible.
  • Naveris shareholders may earn up to $100.0 million in extra cash tied to future revenue milestones.

CareDx reported the closing of two pivotal transactions that reshape its strategic focus and liquidity profile. The company disclosed a cash inflow from the Eurobio divestiture and a cash outflow for the Naveris purchase, together with performance‑based earn‑out provisions.

Eurobio Sale Completion

The Swedish subsidiary, CareDx AB, along with related laboratory‑product assets, was transferred to Eurobio Scientific S.A. On June 30. Under the purchase agreement, CareDx recognized a cash receipt of $171.7 million, subject to customary adjustments for working capital, cash, and debt.

Naveris Acquisition Finalized

On July 1, CareDx’s merger subsidiary combined with Naveris, Inc. Resulting in Naveris becoming a wholly owned subsidiary. The transaction required a cash payment of $161.8 million, after accounting for Naveris’ cash balance, indebtedness, transaction costs, and net working capital. The contingent payout is linked to the achievement of predetermined revenue thresholds in forthcoming fiscal periods.

Strategic Rationale

Divesting the Swedish laboratory business streamlines CareDx’s product portfolio, while acquiring Naveris broadens its service capabilities in the transplant monitoring space. Both actions are intended to concentrate resources on core offerings and to capture growth opportunities in the rapidly evolving cell‑free DNA diagnostics market.

Impact on Liquidity

The cash received from the Eurobio sale offsets the cash outflow required for the Naveris acquisition, resulting in a net cash effect that supports CareDx’s balance sheet. The company anticipates that the combined effect of these transactions will enhance financial flexibility and enable continued investment in research and development.

Regulatory Disclosure

CareDx issued press releases on June 30 and July 1 to announce the respective closures. The filings satisfy the SEC’s regulations governing disclosures of material corporate actions.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.